KYNB · Kyntra Bio, Inc.
The AI's read
The company has cash expected to last into 2028, and lower costs should preserve more of it. The revised royalty deal also limits what it must pay before keeping later royalties. But the early results for FG-3246 were too weak to continue, and the planned Phase 3 trial depends on a partner or outside funding. The quarter also improved, moving from a $13.1 million loss to a $0.2 million profit. Taken together, the gains and setbacks leave the story mixed.